Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA ...

Insight Molecular Diagnostics forecasts a quarterly cash burn of approximately $8 million in the second half of 2026 while targeting FDA authorization within the year, highlighting significant ongoing investment in regulatory approval efforts.

This Wire brief sits within Fusion42's coverage of Diagnostics.